Navigation Links
Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
Date:10/19/2009

ism and body weight. To date, more than 1,200 overweight or obese individuals have received metreleptin in clinical trials, several of which were 16 weeks or longer in duration. In 2007, results from an initial 24-week, Phase 2 clinical proof-of-concept study in 177 overweight or obese individuals (baseline BMI 27-35 kg/m2) showed that combination treatment with pramlintide/metreleptin (360 mcg/5 mg twice daily) resulted in an average weight loss of 12.7% (25 pounds) from enrollment, significantly more than treatment with pramlintide alone (360 mcg twice daily) who experienced an average weight loss of 8.4% (17 pounds) or metreleptin alone (5 mg twice daily) who experienced an average weight loss of 8.2% (16 pounds).

About Davalintide

Davalintide, a, new molecular entity being evaluated for the treatment of obesity, is an analog of the natural hormone amylin that has enhanced amylin mimetic properties. Amylin is a neurohormone secreted by the pancreas that is known to play a role in the regulation of appetite, food intake and postprandial glucose concentrations. Davalintide is currently being studied as a single agent in a six-month, Phase 2 clinical trial in overweight or obese subjects.

Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

This press release
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015  Oncobiologics, Inc., a biotherapeutics company ... biosimilars, has completed the construction of its GMP ... Cranbury, New Jersey . ... is designed to utilize multiple technologies that enable ... Through the use of the latest single-use technologies, ...
(Date:5/4/2015)... May 4, 2015   HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of advanced ... Godshall , is scheduled to present at the Bank of ... Las Vegas on Thursday, May 14, 2015, at ... webcast of the Company,s presentation at the conference will be ...
(Date:5/4/2015)... May 4, 2015  CytRx Corporation (Nasdaq: ... specializing in oncology, today announced an interim analysis ... studies pairing aldoxorubicin with either gemcitabine or ifosfamide. ... ifosfamide with escalating doses of aldoxorubicin. The combinations ... the lowest dose level of aldoxorubicin (170 mg/m2), ...
Breaking Medicine Technology:Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7
... SUNNYVALE, Calif., Dec. 22 Arrayit Corporation (OTC Bulletin Board: ... that the Company has made a technological breakthrough in the ... which are tiny glass substrates that contain rows and columns ... The advance allows highly precise printing of as many as ...
... , NEW YORK, Dec. 22 Delcath Systems, Inc. (Nasdaq: ... treatment method for primary and metastatic cancers to the liver, ... Scientific Advisory Board, effective immediately. , "We formed our ... our Delcath PHP System(TM) with insight from the leading experts ...
Cached Medicine Technology:Arrayit Corporation Announces Manufacturing Breakthrough 2Arrayit Corporation Announces Manufacturing Breakthrough 3Professor Riccardo Lencioni Joins Delcath Systems' Scientific Advisory Board 2Professor Riccardo Lencioni Joins Delcath Systems' Scientific Advisory Board 3
(Date:5/4/2015)... 04, 2015 Leonardo J. Lozada, M.D., ... physician executive, and William C. Daniel, M.D., Saint Luke’s ... personal invitations from the Secretary of the Air Force ... at the Air War College, Maxwell Air Force Base, ... citizens to senior U.S. and international officers and their ...
(Date:5/4/2015)... Pa. (PRWEB) May 04, 2015 Milton ... ’87, the 2015 Alumnus of the Year, recognizing his ... excellence and philanthropy he sets for MHS students. , ... that can happen when children are provided a top-notch ... and hone their passions,” said Pete Gurt ’85, president ...
(Date:5/4/2015)... York, NY (PRWEB) May 04, 2015 ... specialized insurance programs, announces the expansion of coverage for ... is a leading provider of industry-tailored insurance and proactive ... McNeil & Company, we are dedicated to providing our ... to meet their many evolving needs. We are excited ...
(Date:5/4/2015)... “ LiveSchool ” was featured on ... a look at the latest and coolest applications on ... the host of AppWatch and technology expert, conducted the ... allows teachers to reward students with good behavior. , ... in the classroom. And the good people at ...
(Date:5/4/2015)... May 04, 2015 The American Telemedicine ... state policy reports which identify gaps in coverage and ... ATA issued the State Telemedicine Gaps Reports last September, ... their laws and regulations impact healthcare delivery in their ... result of state actions across the nation, ATA reevaluated ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:Milton Hershey School Names 2015 Alumnus of the Year 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3
... year saga of HIV Positive patient Shenequa Flucas is an ... hold the key to curb its escalation. // ,She ... second baby. Depressed with low self esteem, she is ... she received, that opened her mind rather than closing it. ...
... of beauty are most commonly blamed for lowering self-esteem ... trend, // a lot of marketing companies (including Dove) ... messages in an effective way. ,A new ... more likely to lower the onlooker’s self esteem, contrary ...
... study has highlighted that women exposed to high levels of ... than those who have a smooth sail through life. The ... that evaluated the stress levels of women between 1994 and ... were more likely to die over the next 8 years. ...
... Drugs meant for treatment of Attention Deficit Hyperactivity Disorder ... be subjected to stringent clinical trials to assess the ... ,The decision has been taken following the reports ... warnings should be associated with marketing of such drugs. ...
... of fluid filled plastic teething ring, manufactured by The ... been urged by the Food and Drug Administration to ... ,The contaminated liquid if swallowed or absorbed through ... sickness. Malnourished infants, infants with compromised immune function or ...
... (NY) and Catholic University of America in Washington, D.C. ... between themselves affects the emotional development of the// children. ... the psyche of their children is detailed in the ... ,"A useful analogy is to think about emotional security ...
Cached Medicine News:Health News:Parental Conflicts Lead To Emotional Insecurity In Children 2
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
The AMY method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of amylase activity in serum, plasma and urine....
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
Medicine Products: